Price T Rowe Associates Inc Esperion Therapeutics, Inc. Put Options Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ESPR
# of Institutions
200Shares Held
135MCall Options Held
2.72MPut Options Held
1.3M-
Wasatch Advisors Inc Salt Lake City, UT16.9MShares$38.4 Million0.2% of portfolio
-
Black Rock Inc. New York, NY14MShares$31.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$24.7 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$22.7 Million0.37% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny6.51MShares$14.9 Million0.01% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $152M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...